Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021

HomeCareDx Inc.The iBox Validation Study from the Paris Transplant Group Published in the British Medical Journal

The iBox Validation Study from the Paris Transplant Group Published in the British Medical Journal

The iBox validation study from the Paris Transplant Group has been published in the British Medical Journal.  The news was announced today by CareDx, Inc.

CareDx launched KidneyCare at the American Transplant Congress in June 2019. KidneyCare includes the iBox technology as a prognostic measurement alongside multimodality testing with AlloSure® and AlloMap®. CareDx holds the exclusive rights to commercialize the iBox algorithm in the US, through its partnership with Cibiltech, a Paris-based medical technology company.

“Our BMJ publication shows the algorithm we created can provide standardization across centers worldwide,” said Alexandre Loupy, MD, Director of the Paris Transplant Group. “The iBox risk prediction score may help guide patient monitoring and further improve the design and the development of a valid and early surrogate endpoint for clinical trials.”

The BMJ study’s aim was to validate the iBox integrative system to predict long-term allograft failure. The study assessed the performance of the iBox risk prediction score in 7,557 kidney transplant recipients with a median follow-up time of 7 years, across 10 academic medical centers from the United States and Europe. The iBox risk prediction score combines allograft function, histological and immunological parameters with HLA donor specific antibody profiling, to accurately predict the risk of long-term kidney allograft failure as well as to identify significant changes at the time of therapeutic interventions.

“Transplantation provides an incredibly rich data set and is ripe for using augmented intelligence tools to better assess risk and help physicians better manage their daily patient care. Our next step is clinical utility, which we capture through our OKRA registry measuring outcomes from patients surveilled with KidneyCare,” said Sham Dholakia, MD, DPhil, CareDx’s Senior Vice President of Medical Affairs & Clinical Operations.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy